"We are happy to be partnering with NewBridge Pharmaceuticals," said Nicholas Franco, Axcan's Senior Vice President, International Commercial Operations, "which will enable Axcan's Pylera to be launched in rapidly growing markets in which NewBridge has expertise."
About Helicobacter pylori
The discovery in 1983 of the Helicobacter pylori organism was one of the major advances in gastroenterology in recent decades, as it has revolutionized the approach to many upper gastrointestinal disorders. Helicobacter pylori is believed to cause a spectrum of diseases in humans, including gastritis, ulcer disease (gastric and duodenal), gastric cancer and gastric lymphoma. In North-America, 10% of the population will have an ulcer in their lifetime; and many treatments end up with a high rate of recurrences. In fact, 40% to 80% of patients experience a recurrence within only a year after undergoing short-term treatment of gastric acid suppression therapy. Studies have shown that the gastroduodenal reoccurrence rate is only 2% for patients in whom the organism has been eradicated.
About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals (www.nbpharma.com) is a specialty pharmaceutical, biologics, and medical device company serving the Middle East, Africa, Turkey, and Caspian regions to address the unmet needs of diseases with high regional prevalence such as cancer, diabetes, obesity, cardiovascular diseases and other metabolic disorders. NewBridge in-licenses and commercializes FDA and EMEA approved therapeutics, medical devices and diagnostics. Headquartered in UAE with Business Development in the US, NewBridge was founded in 2007 by Burrill & Comp
|SOURCE NewBridge Pharmaceuticals|
Copyright©2009 PR Newswire.
All rights reserved